PE20060944A1 - Formulaciones de derivados de [1,4]diazepina [6,7,1-ij]quinolina - Google Patents

Formulaciones de derivados de [1,4]diazepina [6,7,1-ij]quinolina

Info

Publication number
PE20060944A1
PE20060944A1 PE2005001293A PE2005001293A PE20060944A1 PE 20060944 A1 PE20060944 A1 PE 20060944A1 PE 2005001293 A PE2005001293 A PE 2005001293A PE 2005001293 A PE2005001293 A PE 2005001293A PE 20060944 A1 PE20060944 A1 PE 20060944A1
Authority
PE
Peru
Prior art keywords
composition
weight
component based
diazepine
alkyl
Prior art date
Application number
PE2005001293A
Other languages
English (en)
Inventor
Angela Lin
Wendy A Dulin
Mannching S Ku
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20060944A1 publication Critical patent/PE20060944A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN COMPUESTO DE FORMULA (I) DONDE R1 ES H, ALCANOILO(C2-C6), ENTRE OTROS; R2 Y R3 SON OH, ALCOXI(C1-C6), ENTRE OTROS; R4 Y R5 SON ALQUILO(C1-C6); R6 Y R7 SON ALQUILO(C1-C6); n ES 1 O 2 Y UNA LINEA PUNTEADA REPRESENTA UN DOBLE ENLACE OPCIONAL. UN COMPUESTO PREFERIDO ES CLORHIDRATO (9aR,12aS)-4,5,6,7,9,9a,10,11,12,12a-DECAHIDROCICLOPENTA[c][1,4]DIAZEPINA[6,7,1-ij]QUINOLINA. DICHA COMPOSICION COMPRENDE: A) DE 10% A 80% EN PESO DE LA COMPOSICION DE UN PRINCIPIO ACTIVO DE FORMULA (I); B) DE 10% A 80% EN PESO DE LA COMPOSICION DE UN COMPONENTE DE RELLENO A BASE DE LACTOSA, ALMIDON; C) DE 0,01% A 5% EN PESO DE LA COMPOSICION DE UN COMPONENTE DE RECUBRIMIENTO Y SELLADO A BASE DE CELULOSA; D) DE 0,01% A 20% EN PESO DE LA COMPOSICION DE UN COMPONENTE DE RECUBRIMIENTO ENTERICO A BASE DE POLIMERO SECO, ACRILATO-METACRILATO; E) DE 0.01% A 20% EN PESO DE LA COMPOSICION DE UN DESLIZANTE A BASE DE TALCO, DIOXIDO DE SILICONA; F) DE 0.01% A 3% EN PESO DE LA COMPOSICION DE UN PLASTIFICANTE TALES COMO TRIETIL CITRATO, SORBITOL; G) DE 0.01% A 1,5% EN PESO DE LA COMPOSICION DE UN NEUTRALIZADOR TAL COMO NAOH; H) DE 0.001% A 1% EN PESO DE LA COMPOSICION DE UN TENSOACTIVO TAL COMO POLISORBATO 80 Y I) DE 0.01% A 5% EN PESO DE LA COMPOSICION DE UN LUBRICANTE TAL COMO ACEITE VEGETAL. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE LA ESQUIZOFRENIA
PE2005001293A 2004-11-05 2005-11-03 Formulaciones de derivados de [1,4]diazepina [6,7,1-ij]quinolina PE20060944A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62528004P 2004-11-05 2004-11-05

Publications (1)

Publication Number Publication Date
PE20060944A1 true PE20060944A1 (es) 2006-10-27

Family

ID=35841773

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005001293A PE20060944A1 (es) 2004-11-05 2005-11-03 Formulaciones de derivados de [1,4]diazepina [6,7,1-ij]quinolina

Country Status (19)

Country Link
US (1) US20060110451A1 (es)
EP (1) EP1807088A1 (es)
JP (1) JP2008519057A (es)
KR (1) KR20070084010A (es)
CN (1) CN101094675A (es)
AR (1) AR051946A1 (es)
AU (1) AU2005304758A1 (es)
BR (1) BRPI0517060A (es)
CA (1) CA2586124A1 (es)
GT (1) GT200500318A (es)
IL (1) IL182800A0 (es)
MX (1) MX2007005478A (es)
NO (1) NO20072169L (es)
PE (1) PE20060944A1 (es)
RU (1) RU2007114079A (es)
SV (1) SV2006002293A (es)
TW (1) TW200630100A (es)
WO (1) WO2006052887A1 (es)
ZA (1) ZA200703623B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500317A (es) * 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
AR054849A1 (es) * 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
WO2007112014A2 (en) * 2006-03-24 2007-10-04 Wyeth New therapeutic combinations for the treatment of depression
PA8720401A1 (es) * 2006-03-24 2008-12-18 Wyeth Corp Metodos para tratar trastornos cognitivos y otros afines
AU2007230997A1 (en) * 2006-03-24 2007-10-04 Wyeth Treatment of pain
EP2018863B9 (en) 2006-05-16 2015-02-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
CL2008002777A1 (es) * 2007-09-21 2010-01-22 Wyeth Corp Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
WO2009063992A1 (ja) 2007-11-15 2009-05-22 Takeda Pharmaceutical Company Limited 縮合ピリジン誘導体およびその用途
CA2962959C (en) * 2014-10-08 2023-04-04 Synthetic Biologics, Inc. Beta-lactamase formulations and uses thereof
US10945974B2 (en) 2015-06-01 2021-03-16 Xeno Biosciences Inc. Methods and compositions to modulate the gut microbiota and to manage weight
CN105920017B (zh) * 2016-06-08 2018-06-05 广州嘉德乐生化科技有限公司 一种治疗单纯性肥胖症的药物组合物及其用途
AU2017368074A1 (en) * 2016-11-30 2019-06-13 Xeno Biosciences Inc. Pharmaceutical preparations and methods to manage weight and to modulate the gut microbiota
WO2019131902A1 (ja) 2017-12-27 2019-07-04 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
CN111743976A (zh) * 2020-07-03 2020-10-09 广西医科大学 一种二氧化硅气凝胶在制备治疗骨关节炎药物中的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3158619A (en) * 1962-06-14 1964-11-24 Searle & Co Certain sulfur-containing ortho-fused polycyclic pyrazole derivatives
US3235564A (en) * 1964-03-27 1966-02-15 Searle & Co Intermediates to certain sulfur-containing ortho-fused polycyclic pyrazole derivatives
US3296252A (en) * 1964-04-02 1967-01-03 Sandoz Ag Tetracyclic diazepinone compounds
US3335134A (en) * 1964-04-02 1967-08-08 Sandoz Ag Certain 3, 4-dihydrofluoreno[1, 9a, 9-e, f]1, 4-diazepin-3(2h)-ones
GB1120463A (en) * 1964-07-06 1968-07-17 Manuf Prod Pharma Derivatives of 1,3-diazafluoranthene-1-oxide
US3417101A (en) * 1964-11-09 1968-12-17 American Home Prod Fused ring compounds
US3329676A (en) * 1964-11-09 1967-07-04 American Home Prod Fused 1, 4-diazepine ring systems
US3714149A (en) * 1969-11-03 1973-01-30 Upjohn Co Pyridobenzodiazepinones
US3914250A (en) * 1974-08-01 1975-10-21 American Home Prod 1,4-Diazepino{8 6,5,4-jk{9 carbazoles
US4880814A (en) * 1987-11-13 1989-11-14 Abbott Laboratories 7-cycloalkyl naphthyridines
GB8812636D0 (en) * 1988-05-27 1988-06-29 Glaxo Group Ltd Chemical compounds
EP0357417A1 (en) * 1988-09-01 1990-03-07 Glaxo Group Limited Lactam derivatives
NZ314105A (en) * 1996-02-02 1997-12-19 Sumitomo Pharma Guanidine derivative substituted with a substituted indole which is peri condensed with a heterocyclic ring
US6380166B1 (en) * 1999-09-13 2002-04-30 American Home Products Corporation Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1H-indol-5-ols
US6761904B2 (en) * 2000-03-31 2004-07-13 Nycomed Austria Gmbh Pharmaceutical kit comprising midodrine as active drug substance
AR031197A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Procedimiento para la preparacion de derivados de 1,2,3,4,8,9,10,10a-octahidro-7bh-ciclopenta(b) diazepino(6,7,1-hi)indol
AR031196A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Procedimiento para la preparacion de ciclopenta (b) (1,4)-diazepino (6,7,1-hi) indoles y derivados
AR031199A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Ciclohepta/b//1,4/diacepino/6,7,1-hi/indoles y derivados
AR031202A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Ciclopenta(b) (1,4)diazepino(6,7,1-hi) indoles y derivados
AR031200A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Cicloocta [b] [1,4] diazepino [6,7,1-hi] indoles y derivados
US6414144B1 (en) * 2000-11-03 2002-07-02 Wyeth Process for preparation of cyclopenta[b][1,4]diazepino[6,7,1-hi] indole derivatives
US6503900B2 (en) * 2000-11-03 2003-01-07 Wyeth [1,4]diazepino [6,7,1-jk ]carbazoles and derivatives
US6916922B2 (en) * 2000-11-03 2005-07-12 Wyeth Process for the preparation of 1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta [B] [1,4] diazepino- [6,7,1-hi] indole derivatives
CA2432185C (en) * 2000-12-20 2011-11-08 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
US6825198B2 (en) * 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
CA2453219A1 (en) * 2001-08-06 2003-02-20 Pharmacia & Upjohn Company Therapeutically useful tetracyclic ligands
TW200307682A (en) * 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TWI312781B (en) * 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307540A (en) * 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
EP1581221B1 (en) * 2002-12-19 2011-05-18 Bristol-Myers Squibb Company Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists
EP1592453A1 (en) * 2003-01-28 2005-11-09 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
PA8720401A1 (es) * 2006-03-24 2008-12-18 Wyeth Corp Metodos para tratar trastornos cognitivos y otros afines

Also Published As

Publication number Publication date
MX2007005478A (es) 2007-05-24
SV2006002293A (es) 2006-10-13
US20060110451A1 (en) 2006-05-25
TW200630100A (en) 2006-09-01
AR051946A1 (es) 2007-02-21
WO2006052887A1 (en) 2006-05-18
CN101094675A (zh) 2007-12-26
JP2008519057A (ja) 2008-06-05
BRPI0517060A (pt) 2008-09-30
EP1807088A1 (en) 2007-07-18
NO20072169L (no) 2007-07-24
RU2007114079A (ru) 2008-12-10
KR20070084010A (ko) 2007-08-24
IL182800A0 (en) 2007-09-20
GT200500318A (es) 2006-06-13
CA2586124A1 (en) 2006-05-18
AU2005304758A1 (en) 2006-05-18
ZA200703623B (en) 2009-10-28

Similar Documents

Publication Publication Date Title
PE20060944A1 (es) Formulaciones de derivados de [1,4]diazepina [6,7,1-ij]quinolina
ES2572148T3 (es) Un método para el tratamiento de la enfermedad de Pompe usando 1-desoxinojirimicina y derivados
AR068695A2 (es) Uso de un compuesto de tiazol que comprende un derivado de tiazol para la fabricacion de un medicamento para la prevencion y el tratamiento de en-fermedades causadas por la produccion anormal de citocinas y/o la acele-racion de la adhesion de neutrofilos y/o la produccion anormal de tnf- alfa
ECSP066542A (es) Derivados de disulfuro, sulfuro, sulfóxido, y sulfota de azúcares cíclicos y sus usos
PE20080234A1 (es) Combinacion antiepileptica que comprende derivados de benzoheteroarilsulfamidas
AR059920A1 (es) Compuestos bicicloheteroarilo como moduladores de p2x7 y usos de los mismos
PE20080374A1 (es) Composiciones farmaceuticas de ropinirol
AR018633A1 (es) Derivados de benzo(b)tiepin-1,1-dioxido, procedimiento para su preparacion, medicamentos conteniendo estos compuestos y su empleo
PE20071251A1 (es) Derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
PE20080010A1 (es) Derivados de diazepina para el tratamiento de la depresion y composiciones farmaceuticas que los comprenden
DOP2001000170A (es) Derivados de tiofeno utiles como agentes anticancesoros
AR022303A1 (es) Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
AR045234A1 (es) Metodo para producir derivados del almidon de hidroxialquilo y composiciones farmaceuticas que los contienen.
MA31953B1 (fr) Nouveaux derives du thiophene.
RS49850B (sr) Derivati 1,4-benzotiazepin-1,1-dioksida supstituisani radikalima šećera, postupak za njihovu proizvodnju, lekovi koji sadrže ova jedinjenja i njihova primena
CO5550444A2 (es) Pirazolpirimidinas como agentes terapeuticos
PE20131463A1 (es) Piperidino-dihidrotienopirimidinas sustituidas
RS52562B (en) (3-ARIL-PIPERAZINE-1-IL) DERIVATI 6,7-DIALCOKSIQUINZOLINE, 6,7-DIALCOKSIFTALAZINE I
PE20071325A1 (es) Derivados de n-heteroaril-carboxamidas triciclicas que contienen un resto bencimidazol, su preparacion y su aplicacion en terapeutica
PA8580301A1 (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
CR10236A (es) Modulares del indol sulfonamida de receptores de progesterona
AR065509A1 (es) Derivados heterociclicos de imidazol, composiciones farmaceuticas que los comprenden y uso de los mismos en trastornos inflamatorios y autoinmunes.
TW200833324A (en) Sulfonamide derivatives
AR053453A1 (es) Derivados de aminoalquil- y amidoalquil-benzopirano substituidos
PE20080378A1 (es) Derivados tiofeno-pirazolalcanamida con actividad sobre los receptores ampa

Legal Events

Date Code Title Description
FC Refusal